Abstract:Abstract Background Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. In recent years, more and more somatic mutations and their clinical significance were identified in AML. Most AML patients carry multiple gene mutations and the repertoire of mutations changing during the disease process, which determine the patient's unique clinical manifestations. Herein we recommend using the novel word ”mutaome¡± for representing the repertoire of somatic gene mutations in a specific tumor tissue, and aimed to establish a panel of mutation profiling protocol and retrospective profiling using archived bone marrow smear for clinical use in AML. Methods and Cases Mutation profiling protocol for CEBPA, DNMT3A, FLT3-ITD/TKD, IDH1, IDH2, KIT, NPM1, PHF6 and TET2 by PCR and Sanger sequencing was established, with the detection sensitivity about 15% to 20%. Bone Marrow (BM) or peripheral blood (PB) was collected form patients with newly diagnosed or relapsed. Archived BM smear on glass slides at the time of newly diagnosed were used for retrospective mutation analysis. Results 1) Totally 61 archived smear, 106 fresh BM or PB and 2 paraffin-embedded pathological specimens from 157 patients were analyzed. Age ranged from 1 to 77 years old, with the median age of 27 years old. 2) 60.4% (102/169) samples carrying at least one mutation, 51.0% (53/102) of them carrying 2 or more mutations, 30.4% (31/102) carrying mutations within 2 or more different genes. The number of mutated sample for each gene is 33 for CEBPA¡¢9 DNMT3A¡¢35 FLT3¡¢6 IDH1¡¢7 IDH2¡¢7 KIT¡¢19 NPM1¡¢8 PHF6¡¢and 21 TET2. 3) Paired archived smear and relapsed samples were analyzed for 11 cases, 9 of them showing difference, detailed results shown in Table 1. 4) Totally 53 patients come to our hospital after certain treatment, with the tumor cells below 15% and without AML gene mutation results. For these patients, archived BM smear samples were used for retrospective mutation profiling and then to guide targeted therapy and stratified evaluation. Conclusions Panel testing for gene mutations is effective method for detection of AML molecular markers. For the patients came with partial remission and without gene mutation result, archived bone marrow smear sample can be used for retrospective mutation analysis and then help guiding targeted therapy and stratified evaluation. Disclosures: No relevant conflicts of interest to declare.

Mutaome profile of 10 common mutated genes in refractory and relapsed acute myeloid leukemia

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Mutaome analysis including 10 common mutated genes in newly diagnosed acute myeloid leukemia patients

FLT3 and NPM1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Normal Cytogenetics

Prognostic utility of six mutated genes for older patients with acute myeloid leukemia.

MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.

Co-mutation Landscape and Its Prognostic Impact on Newly Diagnosed Adult Patients with NPM1 Mutated De Novo Acute Myeloid Leukemia.

The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia

Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients

Mutaome Profiling And Retrospective Mutaome Profiling Using Archived Bone Marrow Smear In Aml

Mutations of Epigenetic Modifier Genes As A Poor Prognostic Factor in Acute Promyelocytic Leukemia under Treatment with All-Trans Retinoic Acid and Arsenic Trioxide

Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia

[Analysis of Genomic Landscape in Patients with Acute Myeloid Leukemia]

Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing

The correlation of next-generation sequencing-based genotypic profiles with clinicopathologic characteristics in NPM1-mutated acute myeloid leukemia

[Mutational Spectrum and Prognosis Analysis of AML Patients Based on High-Throughput Sequencing]

[Clinical Characteristics and Prognostic Relevance of Co-Mutated Genes in Acute Myeloid Leukemia Patients with FLT3 Mutations]

Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients

Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next‐generation sequencing technique

Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with RUNX1-RUNX1T1 or CBFB-MYH11 Fusions